Industry Has Eye For Ophthalmic Uses Of Angiogenesis Inhibitors
This article was originally published in The Pink Sheet Daily
Executive Summary
New approaches to controlling blood vessel overgrowth, pioneered in oncology, are transforming retinopathy research. Two of the most advanced agents, Pfizer/Eyetech's Macugen and Genentech's Lucentis, block VEGF activity, while Alcon's Phase III candidate Retaane acts later in the angiogenic cascade. Small interfering RNA and gene therapy would work earlier, stopping production of angiogenic factors.
You may also be interested in...
FDA Agrees To Pivotal Protocol For Oxigene’s Vascular Disrupting Agent Zybrestat
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.
FDA Agrees To Pivotal Protocol For Oxigene’s Vascular Disrupting Agent Zybrestat
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.
Pfizer/Eyetech Sets Sights On Diabetic Macular Edema For Macugen Sales Growth
Eyetech and Pfizer will initiate a Phase II/III pivotal trial during the second half of the year, Eyetech said. The age-related macular degeneration market, for which Macugen is currently approved, may face increasing competition